Market Newsdesk

HOLON, Israel, March 9, 2021 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the publication of a review article titled “Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis” reviewing the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy. The peer-reviewed article, published in Cancer Discovery, a journal of the American Association for Cancer Research, was co-authored by Drew Pardoll, M.D., Ph.D., Professor of Oncology, Johns Hopkins University and Chairman of Compugen’s Scientific Advisory Board.

Article highlights include: 

• Detailed overview of the DNAM-1 axis including axis checkpoint molecules:  DNAM-1, TIGIT, PVRIG and CD96, along with their ligands PVR and PVRL2
• Summary of recent studies outlining the ascendancy of the DNAM-1 axis as a potential new pathway in immuno-oncology, including ongoing clinical trials evaluating therapeutic antibodies directed against TIGIT and PVRIG
• Author commentary on the rationale for testing combination regimens of DNAM-1 axis blockers in combination with PD-1/L1 agents and the overall promise of these emerging targets in cancer clinical trials
• Author discussion of the potential biomarkers that can define patient populations most likely to respond to the blockade of each checkpoint pathway

 

“Our discovery of PVRIG as a distinct pathway in the DNAM axis has evolved into a deep and broad understanding of this potentially foundational axis in cancer immunotherapy,” said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. “Having spent several years studying PVRIG and TIGIT, the latter of which we discovered along with others, as well as their possible synergy with the PD-1 pathway, we are proud to now share our knowledge with the scientific and healthcare communities through this comprehensive review written with Dr. Pardoll, a world-renowned immuno-oncology thought leader and one of our trusted advisors and long-term collaborators. This article provides an overview of the biology that underlies our clinical strategy addressing the DNAM axis, including evidence that supports PVRIG and TIGIT as important and distinct immunotherapy checkpoints in oncology as well as their potential to expand immuno-oncology treatment options to new patient populations. Importantly, with wholly-owned clinical candidates targeting both PVRIG and TIGIT, we are uniquely positioned to evaluate the role of the DNAM axis in the clinic, specifically with our ongoing Phase 1/2 study, evaluating the triple simultaneous blockade of PVRIG, TIGIT and PD-1.”

Dr. Pardoll added, “Our long-standing partnership with Compugen has led to important contributions in the immuno-oncology space, expanding the understanding of the biology of newly discovered immune checkpoints identified by Compugen, including PVRIG and TIGIT. This review highlights the power of these discoveries in the DNAM axis, and the potential of these axis members to translate to new immuno-oncology treatments.”

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen’s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen’s antibody targeting TIGIT, is in a Phase 1 clinical study. Compugen’s therapeutic pipeline also includes early stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen’s corporate website at www.cgen.com.  

Forward-Looking Statement 

This press release contains “forward-looking statements” within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the current beliefs, expectations and assumptions of Compugen. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” “plan,” “goal,” “estimate,” “likely,” “should,” “confident,” and “intends,” and similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen’s operations could be affected by the outbreak and spread of COVID-19, clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product, or may not be able to conduct or complete its trials on the timelines it expects; Compugen relies, and expects to continue to rely, on third parties to conduct its clinical trials and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the COVID-19), Compugen may experience significant delays in the conduct of its clinical trials; Compugen’s approach to the discovery of therapeutic products is based on its proprietary computational target discovery infrastructure, which is unproven clinically; Compugen does not know whether it will be able to discover and develop additional potential product candidates or products of commercial value; Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties; and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. These risks and other risks are more fully discussed in the “Risk Factors” section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law. 

Company contact:

Elana Holzman

Director, Investor Relations and Corporate Communications Compugen Ltd.
Email: [email protected]  
Tel: +972 (3) 765-8124

Investor Relations contact:

Bob Yedid

LifeSci Advisors, LLC
Email: [email protected]    
Tel: +1 (646) 597-6989

Media contact:

Josephine Belluardo, Ph.D.
LifeSci Communications 
Email: [email protected]
Tel: +1 (646) 751-4361

View original content:http://www.prnewswire.com/news-releases/compugen-publishes-review-on-biology-and-potential-therapeutic-relevance-of-dnam-1-axis-in-cancer-immunotherapy-301243088.html

SOURCE Compugen Ltd.

NESS ZIONA, Israel, March 9, 2021 /PRNewswire/ — Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis (ALS).

Specifically, the patent allows for the innovative method of non-genetically modifying a cell population of human progenitor astrocytes or astrocytes, for use in the treatment or prevention of the progression of ALS in a human subject in need and screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) by using this cell population.

Kadimastem’s flagship product, AstroRx^®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.  Kadimastem recently announced encouraging results of the Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS. See press release here.

The technology was first initiated at the Weizmann Institute of Science while Professor Michel Revel, the co-founder of Kadimastem, was a principal investigator there.  It continues to be developed by the experienced and dedicated team in the laboratories of Kadimastem, where Professor Revel serves as the Chief Scientific Officer.

Kadimastem CEO Asaf Shiloni said, “The patent granted by the Israel Patent Office is a significant step forward towards bringing AstroRx® to market for the benefit of ALS patients worldwide.  We aim to have a pre-IND meeting with the US FDA in the near future, with the goal of setting in motion the next stage of clinical trials as soon as possible.  In the meantime, we shall continue our groundbreaking research and development programs for both our ALS and diabetes products.”

Kadimastem Chief Scientific Officer Professor Michel Revel added, “Israel is an important market for research and development and for setting international medical standards and precedent. Today’s patent is an important milestone that supports producing the cells for AstroRx® in Israel for use worldwide.”

About Kadimastem
 

Kadimastem is a clinical stage cell therapy company, developing and manufacturing “off-the-shelf”, allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells.  AstroRx®, the Company’s lead product, is an astrocyte cell therapy in clinical development as a treatment for ALS.  IsletRx is the Company’s second product in development.  IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes.  IsletRx demonstrated safety and efficacy in a proof-of-concept preclinical study.  Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science.  Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Forward Looking Statement

This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company’s activity, as well as developments in the general environment and external factors affecting the Company’s activity. The Company’s results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company’s securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future.

Social Media: LinkedIn, Twitter, Facebook

Company Contacts:
Yossi Nizhar
CFO
[email protected]
+972-73-797-1604

Marjie Hadad

General Manager
Must Have Communications
917-790-1178
[email protected] 

 

 

View original content:http://www.prnewswire.com/news-releases/kadimastem-granted-a-patent-in-israel-for-the-directed-differentiation-of-astrocytes-from-human-pluripotent-stem-cells-astrorx-for-use-in-drug-screening-and-the-treatment-of-als-301243132.html

SOURCE Kadimastem

CORVALLIS, Ore., March 9, 2021 /PRNewswire/ — Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”), a leading smart glass technology company that has developed and is commercializing patented thin-film solutions, today announced the appointment of two new members to its Board of Directors: Gizman Abbas and Gary Hanna.

“It is our pleasure to welcome Gizman and Gary to Crown’s Board of Directors. Both bring decades of experience and wisdom in key areas including global energy solutions, utilities, and executive leadership. We believe their insights will be invaluable to Crown as we continue to execute on our growth strategy into 2021 and beyond, ” said Crown Chairman & CEO, Doug Croxall.

Mr. Abbas currently serves as a Principal of Capital Formation and, Financing & Structuring, for Direct Invest Development and board member of Abu Dhabi Property Leasing Holding Company. Prior to Direct Invest Development, Mr. Abbas was a Founding Partner in Twenty First Century Utilities, a firm focused on adoption of clean low-cost energy. Before that, Mr. Abbas was the Managing Director in Di Development. He also served as a commodities sector investor at Goldman Sachs as a Vice President and at Apollo Global Management where he was a Founding Partner of the commodities investment business.  Prior to that, he was an investment banker at Morgan Stanley focused on M&A, IPOs, and debt financing. Mr. Abbas has extensive board experience, including membership as an independent board member. Mr. Abbas received a BS in Electrical Engineering from Auburn University and an MBA from Kellogg School of Management at Northwestern University

Mr. Hanna has 40 years of management and board experience in the energy sector, primarily in the exploration & production and service areas, with a focus in the Permian, Mid-Continent and Gulf of Mexico regions. Mr. Hanna most recently served as Chairman and Interim CEO for Rosehill Resources from 2017 to 2020. Prior to Rosehill Resources, Mr. Hanna was the Chairman of Energy XXI Gulf Coast where he assisted in evaluating, organizing and executing the sale of Energy XXI Gulf Coast to Cox Oil & Gas. Prior to that, Mr. Hanna was a board member of Aspire Holdings Corp and a member of the Audit Committee from 2017-2018, as well as a board member of Hercules Offshore as a member of the Compensation Committee from 2016-2017. In the past Mr. Hanna held the position of President & Chief Executive Officer of Gulfport Energy Corp., President & Chief Executive Officer at Admiral Energy Services, Inc., Senior Vice President of TETRA Technologies, Inc. President & Chief Executive Officer at Maritech Resources LLC and President for TETRA Applied Technologies LLC (both are subsidiaries of TETRA Technologies, Inc.), Chairman, President & Chief Executive Officer at EPL Oil & Gas, Inc., Chief Executive Officer & Director at KLR Energy Acquisition Corp. and Chief Operating Officer at DLB Oil & Gas, Inc. He received an undergraduate degree from the University of Oklahoma.

About Crown Electrokinetics
Crown is a smart glass technology company and the creator of DynamicTint – We Make Your Glass Smarter™. Originally invented by Hewlett-Packard (HP, Inc.), our technology allows any glass surface to transition between clear and dark in seconds. With applications to a wide array of windows, including commercial buildings, automotive sunroofs, and residential skylights, we partner with leading glass and film manufacturers for mass production and distribution. At the core of our technology is a thin film that is powered by electrically-charged pigment which not only replaces common window tints but is also a more sustainable alternative to traditional window treatments. With its unique ability to be retrofitted to existing glass, DynamicTint™ offers myriad benefits related to reducing carbon emissions. The company is supported by a robust patent portfolio. For more information, please visit WWW.CROWNEK.COM.

Forward-Looking Statements
This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Crown Electrokinetics and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described in Crown Electrokinetics’ periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Crown Electrokinetics undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

 

View original content:http://www.prnewswire.com/news-releases/crown-electrokinetics-appoints-two-new-members-to-its-board-of-directors-301242946.html

SOURCE Crown Electrokinetics

TEL-AVIV, Israel, March 9, 2021 /PRNewswire/ — Nutritional Growth Solutions, Ltd. (NGS), a public company trading in the Australian Stock Exchange (ASX: NGS), is expanding international activities for its Healthy Height® protein shake in China. Healthy Height has been clinically shown to improve children’s height. This step forward is followed by a substantial growth in sales — 58% — in 2020.

This result was driven by a sharp jump in online sales of Healthy Height in the US via Amazon and Shopify. The sales of the company’s proprietary protein powder for children soared in the US during the COVID-19 pandemic, leading to a increasing of consumption on a year-on-year basis.

NGS has signed an agreement with leading child celebrity and social media influencer Gavin Thomas to promote its brand in China. Thomas has more than 8 million followers on Chinese social media platforms, and has graced the cover of China’s edition of ELLE Magazine. He is the youngest recipient of the Weibo Influencer Award (Weibo is a Chinese social media platform similar to Twitter).

Thomas will promote NGS’s Healthy Height product range in China through various social media campaigns, physical appearances, and associated brand ambassador activity. The goal is to drive traffic to NGS’s e-commerce flagship store on Tmall Global. Tmall Global is Alibaba’s b2C cross-border marketplace for international brands and retailers to sell directly to more than half a billion consumers on Alibaba’s platform in China. NGS also is retailing Healthy Height through select “mother and baby” stores.

“Nutritional Growth Solutions and Gavin Thomas are a great match for raising the awareness of our Healthy Height brand in China,” says Liron Fendell, CEO and Managing Director of NGS. “He’s greatly loved by kids and parents alike in China who identify with his quirky personality and engage with him as a person. Gavin also is an authentic user of our products, so he will be able to communicate to Chinese families with integrity about our patented, scientifically formulated and clinically tested nutritional shakes that assist children in reaching their maximum height.”

“Social influencer engagement between brands and consumers through e-commerce platforms is much more advanced and ingrained in China than other markets,” adds Brian Leedman, NGS Chairman. “Partnering with Gavin Thomas is a key to quickly gaining scale in this important market where there is an unmet need for our clinically proven product.”

The severity of the COVID19 pandemic encouraged the general population of China to reconsider their dietary habits. This resulted in a significant rise in popularity for health supplement products on both online and offline sales channels. Increasing per-capita disposable income also allows Chinese consumers to pay more attention to premium foreign brands. As a result, nutritional supplements were among the fastest growing categories on Tmall Global during 2020 with monthly sales exceeding 1B RMB (approx. 200m AUD) with protein powders/amino acids among the largest categories[1]. Healthy Height’s new flagship store on Tmall Global gives Chinese consumers access to the clinically tested protein shakes for children, reflecting increasing demand for high-quality, international nutrition brands in China.

“Chinese parents tend to invest in their children’s nutrition and prefer to purchase well-known brands backed by research,” explains Fendell.

Healthy Height was developed and tested by pediatricians to give a holistic solution to nourish growing children primarily in the 3 to 9-years age group, including those children who lack nutrition due to health issues that can impair eating.

Healthy Height contains 12g whey protein per serving, with high-quality ingredients, and without corn syrup or other additives. It is gluten-free, soy-free, no GMO, and includes 350mg of the vital amino acid arginine per serving. It also is low in sugar and sodium. “Picky eater approved,” Healthy Height can be mixed into ice cream or pancake batters as well as in shakes or smoothies.

About Nutritional Growth Solutions

Nutritional Growth Solutions is a global nutritional health company focused on the well-being of children. NGS develops, produces and market clinically tested nutritional supplement formulae for children following 20 years of medical research into pediatric nutrition at Schneider Children’s Medical Centre, Israel’s largest pediatric hospital.

[1] https://www.tmogroup.asia/china-best-selling-health-supplements-618/

View original content to download multimedia:http://www.prnewswire.com/news-releases/healthy-height-kid-growth-solution-focuses-on-china-301243127.html

SOURCE Nutritional Growth Solutions, Ltd.

SHANGHAI, March 9, 2021 /PRNewswire/ — The9 Limited (NASDAQ: NCTY) (“The9”), an established Internet company, announced today that it will host a conference call and webcast on March 30, 2021 at 8:00 AM, U.S. Eastern Time (corresponding to March 30, 2021 at 8:00 PM, Beijing Time) to discuss The9’s 2020 unaudited financial results and The9’s recent development on the cryptocurrency mining business, which will be released on March 29, 2021. The press release will be available on The9’s Investor Relations website located at https://www.the9.com/en/

Investors, analysts and other interested parties will be able to access the live conference by calling:

Additionally, The9 will also provide a live webcast of the call at https://services.themediaframe.com/links/ncty210330.html 

About The9 Limited

The9 Limited (The9) is an Internet company based in China listed on Nasdaq in 2004. The9 aims to become a diversified high-tech Internet company.

View original content:http://www.prnewswire.com/news-releases/the9-limited-to-report-unaudited-financial-results-on-march-30-2021-301243134.html

SOURCE The9 Limited

FORT WORTH, Texas, March 9, 2021 /PRNewswire/ — Elbit Systems of America will provide the United States Army with continued support and maintenance of the Integrated Helmet and Display Sighting System (IHADSS) that is used by AH-64 Apache pilots. Work will be performed at the company’s Sustainment and Support Solutions’ Component Repair Center of Excellence in Talladega, Alabama.

The IHADSS is a proven Helmet Mounted Display (HMD) for rotary-wing aircraft, with the ability to align turreted weapons, missile seekers, and gimbaled night vision to the pilot’s line of sight. The system also allows cueing between an aircraft’s crew members, helping to ensure mission success and crew safety.

Elbit Systems of America has a legacy providing HMDs to rotary and fixed-wing pilots in multiple military services. Leveraging the company’s vast capabilities and experience, along with its dedication to Integrated Logistics Support, Elbit Systems of America provides the innovative systems its customers require – now and in the future.

“U.S. Army aircraft must always be mission-ready and their crews must be equipped with the very best HMDs on the market. This recent contract enables Apache pilots to continue their missions with confidence,” said Chris Hickey, Vice President of Sustainment and Support Solutions at Elbit Systems of America. “We’ve handled the overhaul and repair effort for the IHADSS for 17 years, and we’re proud to have earned the Army’s trust on this mission-critical system.

About Elbit Systems of America, LLC

Elbit Systems of America, headquartered in Fort Worth, Texas, is a leading provider of high-performance products, system solutions, and support services focusing on the defense, homeland security, law enforcement, commercial aviation, and medical instrumentation markets. With facilities throughout the U.S., Elbit Systems of America is dedicated to supporting those who contribute daily to the safety and security of the United States. Elbit Systems of America, LLC is wholly owned by Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT), a global high technology company engaged in a wide range of programs for innovative defense and commercial applications. For additional information, visit: www.ElbitAmerica.com or follow us on Twitter, LinkedIn and Instagram.

About Elbit Systems

Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance (“C4ISR”), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios, cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems. For additional information, visit: https://elbitsystems.com/, follow us on Twitter or visit our official Facebook, YouTube and LinkedIn Channels.

Trademarks

Elbit Systems of America and other trademarks, service marks and logos are registered or unregistered marks of Elbit Systems of America companies in the United States and in foreign countries. Copyright ©2021 Elbit Systems of America. All rights reserved.

Forward Looking Statement

This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management’s current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies and anticipated trends in its business.  Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings.  The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.’s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.

Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.  All other brand, product, service and process names appearing are the trademarks of their respective holders.  Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.

Media Contacts:

Greg Caires | 682-286-2299 | [email protected] 
Amy Hartley I 682-286-2411 I [email protected]

 

 

 

View original content:http://www.prnewswire.com/news-releases/elbit-systems-of-america-to-provide-us-army-ah-64-apache-ihadss-sustainment-301243105.html

SOURCE Elbit Systems of America, LLC

NEW YORK, March 9, 2021 /PRNewswire/ — Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; the “Company” or “Lindblad”), a global provider of expedition cruises and adventure travel experiences today announced that it has acquired majority stakes in DuVine Cycling + Adventure Co. (“DuVine”), a leading luxury cycling and adventure travel company, and Off the Beaten Path LLC (“Off the Beaten Path”), a leading active travel operator with a specialization in U.S. National Parks.  These acquisitions further broaden and deepen Lindblad’s platform of high-quality experiential product offerings in robust adventure travel sectors, including the rapidly growing cycling tourism and domestic expedition markets. Similar to the acquisition of Natural Habitat, Inc. (“Natural Habitat”), the Company will leverage its experience and resources to accelerate the growth of these unique and profitable businesses and capitalize on the growing demand for authentic and immersive adventure travel.  

DuVine is an award-winning international luxury cycling and adventure company based in Somerville, Massachusetts focused on providing immersive cultural experiences across the globe through thoughtfully designed itineraries led by expert local guides.  DuVine’s trips include top-quality gear and support and are tailored to riders of all abilities with an emphasis on exceptional food and wine experiences, along with boutique accommodations.  DuVine also currently runs a variety of extraordinary trips that combine sailing and biking experiences, which will be further expanded as part of Lindblad.  Founded in 1996 by Andy Levine, DuVine’s diverse tour offerings include small group and private custom trips to destinations across Europe, the United States, Latin America, Asia and Africa.  Mr. Levine will retain an ownership interest in DuVine and will continue as President and Chief Executive Officer of the new Lindblad subsidiary.

Off the Beaten Path, based in Bozeman, Montana, offers active small-group and private custom journeys around the world, with a long-standing focus on U.S. National Parks and connecting the heart of the traveler with the soul of the place through localized, authentic experiences.  Founded in 1986, Off the Beaten Path’s small group product offerings include unique expeditions throughout the U.S., as well as trips across Europe, Africa, Australia, Central and South America and the South Pacific.  Cory Lawrence, Off the Beaten Path’s President and Chief Executive Officer, will retain an ownership interest in Off the Beaten Path and continue in this role for the new Lindblad subsidiary.

DuVine and Off the Beaten Path will benefit from Lindblad’s scale, resources and marketing experience while substantially increasing the addressable opportunity across Lindblad’s portfolio.  The significant demand for cycling-related content and usage was expanding rapidly prior to COVID-19 and that has only accelerated throughout the pandemic. According to the NPD Group, from January through October of 2020 US. bicycle sales increased over 60% and e-bike sales increased 144% compared with the same period in 2019.  DuVine’s proven track record in delivering high-end small group cycling experiences, along with the meaningfully increased accessibility that the evolution of the e-bike provides, ideally situates them to further capitalize on this growing opportunity both immediately coming out of the pandemic and over the long-term.  Similarly, Off the Beaten Path has unique access to limited lodging inventory across its geographies, particularly in U.S. National Parks enabling unmatched exploration in destinations that attract millions of visitors each year.  These remarkable locations will only grow in popularity post pandemic given their proximity and, with a long-standing reputation of delivering authentic small group and private custom travel experiences, Off the Beaten Path is well positioned for sustained growth.  Both DuVine and Off the Beaten Path have been operating trips during COVID and are currently experiencing strong levels of bookings for future travel. 

Sven-Olof Lindblad, President and Chief Executive Officer, said, “Bringing DuVine and Off the Beaten Path into our portfolio of brands will allow us to better serve a broader based clientele that has a diverse set of travel interests. The high level of quality and integrity of both these companies makes them perfect partners in our strategy of expanding our platform of experiential offerings.  Our proven ability to leverage our platform and effectively cross market creates the opportunity to accelerate growth across our entire portfolio, and we will continue to look for additional opportunities to broaden and deepen our adventure travel offerings, both organically and through acquisitions, to aggregate larger audiences and generate greater lifetime value from our loyal guests.”

Andy Levine, DuVine’s Founder and President, stated, “I have long admired Lindblad for their exceptional expeditions and commitment to responsible travel, a core value that has also guided DuVine’s philosophy. Our companies share not only a desire to sustain the world’s most compelling cultures and communities, but also the belief that authentic, deeply-rooted experiences make travel more fulfilling. DuVine’s journeys offer a new perspective grounded in active travel, local flavor, and an appreciation of nature from the seat of a bicycle. I can’t wait to introduce the transformative power of bike travel to a greater audience of adventure seekers.”

Cory Lawrence, Off the Beaten Path’s President, stated, “We couldn’t be more excited to join Lindblad Expeditions and Natural Habitat Adventures to further our mission to change peoples’ lives through exceptional travel experiences. With our unique style of travel, strong domestic presence, and small group and bespoke travel design offerings, we are well-positioned to have immediate impact on the newly expanded family of companies. Expanding awareness of Off the Beaten Path and its unique offerings by leveraging the reach and expertise of both Lindblad and Natural Habitat is a major opportunity for our company in its 35^th year of operation. We are thrilled!”

Mark Ein, Lindblad’s Chairman, added, “From when we first invested in Lindblad in 2015, we have always viewed Lindblad as an opportunity to build an extraordinary platform company that would expand, organically and through acquisition, to offer an unparalleled set of indelible experiences for its guests.  We are proud of what we have already done to date, with incredible new ship builds and the Natural Habitat acquisition, and, over the last year, we focused on securing the capital that would enable us to accelerate our growth coming out of COVID.  We have now found two ideal companies in DuVine, poised to capitalize on the explosive growth in cycling, and Off the Beaten Path, with its unique access to U.S. National Parks, to bring into our Lindblad family.   These are important steps in our continuing quest to solidify Lindblad as one of the finest travel companies in the world.”

About Lindblad Expeditions Holdings, Inc.

Lindblad Expeditions Holdings, Inc. is an expedition travel company that focuses on ship-based voyages through its Lindblad Expeditions brand and on land-based travel through its subsidiaries, Natural Habitat Adventures, Off the Beaten Path and DuVine Cycling and Adventure.

Lindblad Expeditions works in partnership with National Geographic to inspire people to explore and care about the planet. The organizations work in tandem to produce innovative marine expedition programs and to promote conservation and sustainable tourism around the world. The partnership’s educationally oriented voyages allow guests to interact with and learn from leading scientists, naturalists and researchers while discovering stunning natural environments, above and below the sea, through state-of-the-art exploration tools.

Natural Habitat partners with the World Wildlife Fund to offer and promote conservation and sustainable travel that directly protects nature. Natural Habitat’s adventures include polar bear tours in Churchill, Canada, Alaskan grizzly bear adventures and African safaris.

DuVine Cycling + Adventure Co. designs and leads luxury bike tours in the world’s most amazing destinations, from Italy’s sun-bleached villages and the medieval towns of Provence to Portugal’s Douro Valley and the vineyards of Napa, California. Guests bike, eat, drink, and sleep their way through these regions and many more while sampling the finest cuisine, hotels, and wine. 

Off the Beaten Path is an outdoor, active travel company offering guided small group adventures and private custom journeys that connect travelers with the wild nature and authentic culture of their destinations.  Off the Beaten Path’s trips extend across the globe, with a focus on exceptional national park experiences in the Rocky Mountains, Desert Southwest, and Alaska.

 

View original content:http://www.prnewswire.com/news-releases/lindblad-expeditions-holdings-inc-acquires-majority-stakes-in-duvine-cycling–adventure-co-and-off-the-beaten-path-llc-301243067.html

SOURCE Lindblad Expeditions Holdings, Inc.

LAVAL, Quebec, March 9, 2021 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) has published a presentation that Joseph C. Papa, chairman and CEO, Sam Eldessouky, senior vice president and corporate controller, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to present at the Barclays Global Healthcare Conference today, March 9, 2021, at 2:25 p.m. ET.

The presentation, which provides an update on Bausch Health’s current pipeline for Salix, including an update regarding its rifaximin clinical development efforts, is available on the Investor Relations page of the Bausch Health Companies Inc. website at: https://ir.bauschhealth.com/events-and-presentations/2021. A live webcast and audio archive of the event will also be available on the Investor Relations page of the Company’s website.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements

This news release may contain forward-looking statements, which may generally be identified by the use of the words “expects,” “intends,” “plans,” “should,” “could,” “would,” “potential” or “target” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-publishes-pipeline-update-for-the-barclays-global-healthcare-conference-301243006.html

SOURCE Bausch Health Companies Inc.

LISHUI, China, March 9, 2021 /PRNewswire/ — Farmmi, Inc. (“Farmmi” or the “Company”) (NASDAQ: FAMI), an agriculture products supplier in China, today announced its subsidiary Zhejiang Forest Food Co., Ltd., has received a follow-on customer order for its popular dried whole and sliced mushrooms, and dried black fungus. The customer, a trading company supplying to major global hotel and supermarket chains, including the STANFORD hotel chain and the H-MART supermarket chain, will export Farmmi’s products to the United Kingdom.

Ms. Yefang Zhang, Farmmi’s Chairwoman and CEO, commented, “We are increasing sales momentum with each new order, while reinforcing the diversity of our customer base.  The investments we made in strengthening our supply chain, processing and fulfillment capabilities give us a powerful, scalable growth platform. The broader healthy product industry is highly fragmented with significant opportunities for Farmmi to grow our market share as we deliver superior products to meet increasing demand. Importantly, we are unwavering in our focus on driving revenue and profit growth, while building even greater value for shareholders.”

About Farmmi, Inc.

Headquartered in Lishui, Zhejiang, Farmmi, Inc. (NASDAQ: FAMI), is a leading agricultural products supplier, processor and retailer of Shiitake mushrooms, Mu Er mushrooms and other edible fungi.  For further information about the Company, please visit: http://ir.farmmi.com.cn/.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including the potential impact of COVID-19 on our business within and outside of China. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results.

View original content:http://www.prnewswire.com/news-releases/farmmi-receives-follow-on-order-for-export-to-the-uk-301242878.html

SOURCE Farmmi, Inc.

SUZHOU, China, March 9, 2021 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial No.: KN046-205) in the United States to evaluate the efficacy, safety and tolerability of KN046 (PD-L1/CTLA-4 bispecific antibody) for the treatment of thymic carcinoma.

Thymic carcinoma is a rare but highly aggressive thymic tumor, and the most aggressive subtype of thymic epithelial tumors, accounting for about 20%. The number of patients with thymic carcinoma is about 4,200 to 6,000 in China per year, and 1,400 to 2,000 in the United States per year. Inoperable or metastatic thymic carcinoma has a very poor prognosis, and there is currently no approved standard treatment for patients who have failed platinum-based chemotherapy. The median overall survival after late-line chemotherapy or targeted therapy is less than 12 months, and there is an urgent need for better options to improve the efficacy.

KN046 is a bispecific antibody targeting PD-L1 and CTLA-4 immune checkpoints. It can more effectively activate T-cells and enhance the T-cells cancer killing ability. In a phase I clinical study conducted in Australia, KN046 showed a 75% disease response rate and 100% disease control rate in patients with thymic epithelial tumors. The research data was presented at the 21^st World Conference on Lung Cancer (WCLC 2020). In September 2020, KN046 was granted the orphan drug designation by the FDA for the treatment of thymic epithelial tumors. In January 2021, the Phase II pivotal clinical trial of KN046 for the treatment of thymic carcinoma (clinical trial No.: ENREACH-Thymic) completed enrollment of the first patient in China.

About KN046
KN046 is PD-L1/CTLA-4 bispecific antibody independently developed by Jiangsu Alphamab. Its innovative designs include: a different mechanism CTLA-4 fused with PD-L1 single domain antibody; engineered to target the tumor microenvironment with high PD-L1 expression, and Treg (suppress tumor immunity) clearing function.

There are about 20 clinical trials of KN046 in different stages covering more than 10 types of tumors including NSCLC, TNBC, ESCC, HCC and pancreatic cancer in Australia and China. The results of these clinical trials have shown an advantage in survival for patients. Alphamab has received FDA clearance to enter phase Ⅱ trial of KN046 based on the clinical results in China and Australia. Moreover, KN046 has obtained the U.S. FDA’s orphan drug designation for thymic epithelial tumor in September 2020. Two pivotal clinical trials are currently being conducted.

About Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. On December 12, 2019, the Company was listed in the mainboard of Hong Kong Stock Exchange with stock code 9966.

Alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. Its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a Covid-19 multifunctional antibody. Four products have advanced into phase I-III clinical trials or pre-marketing stage in China, the United States, Japan and Australia. The BLA for Envafolimab (KN035) has been accepted and granted Priority Review by the National Medical Products Administration (NMPA).

The Company also has state-of-the-art manufacturing capabilities designed and built to meet NMPA and EU/FDA’s cGMP standards and a complete quality system which has passed the on-site inspection of an European Union qualified person. Alphamab Oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in China and around the world.

Visit http://www.alphamabonc.com for more information.

View original content:http://www.prnewswire.com/news-releases/alphamab-received-us-fda-ind-clearance-to-initiate-a-phase-ii-pivotal-clinical-trial-of-kn046-kn046-205enreach-thymic-in-the-us-301243226.html

SOURCE Alphamab Oncology